Intraperitoneal188Re-Liposome delivery switches ovarian cancer metabolism from glycolysis to oxidative phosphorylation and effectively controls ovarian tumour growth in mice

Yao An Shen, Keng Li Lan, Chih Hsien Chang, Liang-ting Lin, Chun Lin He, Po Hung Chen, Te Wei Lee, Yi Jang Lee, Chi Mu Chuang

Research output: Journal article publicationJournal articleAcademic researchpeer-review

11 Citations (Scopus)


Background and purpose Cancer stem cells exhibit distinctive cellular metabolism compared with the more differentiated counterparts or normal cells. We aimed to investigate the impact of a novel radionuclide anti-cancer agent188Re-Liposome on stemness markers' expression and cellular metabolism in an ovarian cancer model. Material and methods A 2 × 2 factorial experiment was designed in which factor 1 represented the drug treatment comparing188Re-BMEDA, a free form of188Re, with188Re-Liposome, a nanoparticle-encapsulated form of188Re. Factor 2 represented the delivery route, comparing intravenous with intraperitoneal delivery. Results Intraperitoneal delivery of188Re-Liposome predominantly killed the CSCs-like cells in tumours and switched metabolism from glycolysis to oxidative phosphorylation. Further, intraperitoneal delivery of188Re-Liposome treatment was able to block epithelial-to-mesenchymal transition (EMT) and reactivate p53 function. Collectively, these molecular changes led to a striking tumour-killing effect. Conclusions Radionuclides encapsulated in liposomes may represent a novel treatment for ovarian cancer when delivered intraperitoneally (a type of loco-regional delivery). In the future, this concept may be further extended for the treatment of several relevant cancers that have been proved to be suitable for loco-regional delivery of therapeutic agents, such as colon cancer, gastric cancer, and pancreatic cancer.
Original languageEnglish
Pages (from-to)282-290
Number of pages9
JournalRadiotherapy and Oncology
Issue number2
Publication statusPublished - 1 May 2016
Externally publishedYes


  • 188 Re
  • Cancer stem cell
  • Liposome
  • Metabolic reprogramming
  • p53

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this